0.841

3.33% -0.029

After Hours: .82 -0.021 -2.50%

Chemomab Therapeutics Ltd ADR (CMMB)

Overview News Price History Financials Discussions Forecast

Chemomab Therapeutics Ltd ADR stock is currently priced at $0.841, with a 24-hour trading volume of 54,633. It has seen a -3.33% decreased in the last 24 hours and a +42.54% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.8555 pivot point. If it approaches the $0.8309 support level, significant changes may occur.

Previous Close:

$0.87

Open:

$0.8656

24h Volume:

54,633

Market Cap:

$11.96M

Revenue:

Net Income/Loss:

$-33.08M

P/E Ratio:

-0.2861

EPS:

-2.94

Net Cash Flow:

$-25.68M

1W Performance:

+0.24%

1M Performance:

+42.54%

6M Performance:

+47.75%

1Y Performance:

-53.28%

1D Range:

$0.8265

$0.88

52W Range:

$0.42

$1.89

Chemomab Therapeutics Ltd ADR Stock (CMMB) Company Profile

Name

Chemomab Therapeutics Ltd ADR

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

972 77 331 0156

Address

Building 7, Kiryat Atidim, Tel Aviv

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

CMMB's Discussions on Twitter

Chemomab Therapeutics Ltd ADR Stock (CMMB) Latest News

Roth MKM Initiates Coverage of Chemomab Therapeutics Ltd - ADR (CMMB) with Buy Recommendation - MSN

MSN

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

GlobeNewswire Inc.

Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?

Zacks Investment Research

Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy? - Zacks Investment Research

Zacks Investment Research

New Strong Sell Stocks for March 14th - Yahoo Canada Shine On

Yahoo Canada Shine On

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

GlobeNewswire Inc.

Chemomab Therapeutics Ltd ADR Stock (CMMB) Financials Data

Chemomab Therapeutics Ltd ADR (CMMB) Net Income 2024

CMMB net income (TTM) was -$33.08 million for the quarter ending June 30, 2023, a -71.39% decrease year-over-year.

Chemomab Therapeutics Ltd ADR (CMMB) Cash Flow 2024

CMMB recorded a free cash flow (TTM) of -$25.68 million for the quarter ending June 30, 2023, a -70.66% decrease year-over-year.

Chemomab Therapeutics Ltd ADR (CMMB) Earnings per Share 2024

CMMB earnings per share (TTM) was -$2.94 for the quarter ending June 30, 2023, a -75.00% decline year-over-year.

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.